Immediate Medical Therapy for Severe PAD
Start aspirin 75-100 mg daily and a high-intensity statin (e.g., atorvastatin 40-80 mg or rosuvastatin 20-40 mg) immediately—these are foundational therapies that reduce cardiovascular death, myocardial infarction, and stroke in all patients with PAD, regardless of symptom status. 1, 2
Antiplatelet Therapy: Choose Your Strategy
For this 89-year-old with severe bilateral infra-popliteal disease, you have two evidence-based options:
Option 1: Single Antiplatelet Therapy (Simpler, Lower Bleeding Risk)
- Clopidogrel 75 mg daily is preferred over aspirin alone for PAD 1, 3
- Alternative: Aspirin 75-100 mg daily if clopidogrel is contraindicated
- This is the safer choice given her age and likely frailty
Option 2: Dual Pathway Inhibition (More Aggressive, Higher Efficacy)
- Rivaroxaban 2.5 mg twice daily PLUS aspirin 100 mg daily should be considered for patients with high ischemic risk and non-high bleeding risk 1, 2
- This combination reduces both MACE (cardiovascular death, MI, stroke) and MALE (acute limb ischemia, amputation, revascularization) more effectively than aspirin alone
- Critical caveat: Increases major bleeding risk—exclude if she has:
- History of intracranial hemorrhage or stroke
- GI bleeding within 6 months
- Severe kidney disease (CrCl <15 mL/min)
- High fall risk given her age 1
My recommendation: Given her age (89 years) and severe disease, start with clopidogrel 75 mg daily as the safer initial approach. The dual pathway strategy (rivaroxaban + aspirin) offers superior limb and cardiovascular protection but requires careful bleeding risk assessment that may be better evaluated at her vascular appointment.
Lipid Management: High-Intensity Statin
- Start atorvastatin 40-80 mg daily OR rosuvastatin 20-40 mg daily 1, 4, 5
- Target LDL-C <70 mg/dL (ideally <55 mg/dL for very high-risk patients)
- If she has chronic kidney disease (common with PAD), rosuvastatin 10-20 mg may be preferred initially 6
- Statins reduce cardiovascular events and mortality in PAD independent of cholesterol levels
Additional Immediate Actions
Blood Pressure Control
- Target <130/80 mmHg if tolerated
- ACE inhibitors or ARBs are preferred, especially if she has diabetes or CKD 1, 4
Diabetes Management (if applicable)
- GLP-1 receptor agonists (e.g., semaglutide) or SGLT2 inhibitors reduce cardiovascular events and may reduce limb events 3, 5
- These are preferred over other antidiabetic agents in PAD
Smoking Cessation (if applicable)
Vaccinations
- Influenza and COVID-19 vaccines are recommended 1
What NOT to Start Yet
- Cilostazol: This is for symptomatic claudication relief, not cardiovascular protection—wait to see if she's actually symptomatic 1, 6
- Dual antiplatelet therapy (aspirin + clopidogrel): Only indicated post-revascularization, not for medical management alone 1
Critical Pitfalls to Avoid
- Don't confuse symptomatic therapy with risk reduction: Cilostazol improves walking distance but doesn't prevent heart attacks or strokes—antiplatelet agents and statins do 6
- Don't delay statin therapy: Even at age 89, statins reduce cardiovascular events in PAD 5
- Don't use triple therapy: Full-dose anticoagulation + dual antiplatelet therapy dramatically increases bleeding risk 1
- Assess bleeding risk carefully: At 89 years, fall risk and frailty matter—if uncertain about rivaroxaban, stick with clopidogrel alone
Before Her Vascular Appointment
Document:
- Current walking distance and any rest pain (to assess for chronic limb-threatening ischemia)
- Foot examination findings (pulses, temperature, wounds, infection)
- Renal function (affects medication dosing)
- Bleeding history and fall risk (affects antithrombotic choice)
The vascular team will determine if she needs revascularization, but medical therapy should start now—it's equally important whether or not she undergoes intervention 1, 7.